TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11230031
Drug: Cognitive-analytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-analytic therapy (CAT) for 7 months
Study: 11230031
Drug: Family therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family therapy for 1 year
Study: 11230031
Drug: Low contact,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low contact, 'routine' treatment for 1 year
Study: 3427224
Drug: Cyclophosphamide plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide plus Adriamycin followed by high-dose methotrexate plus cisplatin
Study: 3427224
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate plus cisplatin followed by Cyclophosphamide plus Adriamycin
Study: 21597989
Drug: Methylphenidate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (all doses)
Study: 18334815
Drug: Beta-glucan-enriched ready
Normalized name: yeast, beta-D-glucan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-glucan-enriched ready meal (4 g of oat beta-glucans)
Study: 9322828
Drug: Valsartan 80/160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80/160 mg
Study: 9322828
Drug: Valsartan 80/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 80/80 mg twice daily
Study: 9322828
Drug: Lisinopril 10/20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 10/20 mg
Study: 9322828
Drug: Valsartan and
Normalized name: valsartan and aliskiren
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan and Lisinopril
Study: 7690462
Drug: L-697,661 (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-697,661 (25 mg twice a day)
Study: 7690462
Drug: L-697,661 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-697,661 (100 mg three times a day)
Study: 7690462
Drug: L-697,661 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-697,661 (500 mg twice a day)
Study: 7690462
Drug: Zidovudine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zidovudine (100 mg five times a day)
Study: 7690462
Drug: L-697,661 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-697,661 (all doses)
Study: 7690462
Drug: L-697,661 (higher
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-697,661 (higher doses)
Study: 29958570
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron sucrose (200 mg via two infusions)
Study: 29958570
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron polymaltose complex (100 mg orally twice a day for 8 weeks)
Study: 26763349
Drug: Lenalidomide starting
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide starting dose of 5 mg/d
Study: 26763349
Drug: Lenalidomide starting
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide starting dose of 10 mg/d
Study: 26763349
Drug: Lenalidomide starting
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide starting dose of 15 mg/d
Study: 26763349
Drug: Escalated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated treatment (to 15 or 20 mg/d)
Study: 26763349
Drug: Lenalidomide (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (any starting dose)
Study: 24531938
Drug: Periarticular infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Periarticular infiltration analgesia (PIA) with 60 ml 0.5 % ropivacaine and 0.3 mg epinephrine
Study: 24531938
Drug: Sciatic nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sciatic nerve block (SNB) with 20 ml 0.375 % ropivacaine and periarticular infiltration with 20 ml normal saline and 0.3 mg epinephrine
Study: 22218122
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (500 mg, 2 tablets per day for 5 days before transplantation)
Study: 21535171
Drug: Narrow band
Normalized name: Band-Aid Hurt-Free
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow band ultraviolet B (NBUVB) + isotretinoin (0.5 mg/kg/day)
Study: 24645
Drug: Halazepam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halazepam (40 mg starting dose, adjusted every 2 hours, total daily dose not exceeding 600 mg)
Study: 24528686
Drug: Armolipid Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armolipid Plus (nutraceutical combination containing red yeast rice extract, berberine, policosanol, astaxanthin, coenzyme Q10, and folic acid)
Study: 17621463
Drug: Tenofovir DF
Normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenofovir DF (TDF) in combination with lamivudine (3TC) and efavirenz (EFV)
Study: 15304466
Drug: Bivalirudin (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin (0.75 mg/kg bolus, 1.75 mg/kg per hour for the duration of PCI) with provisional Gp IIb/IIIa inhibition
Study: 15304466
Drug: Heparin (65
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (65 U/kg bolus) with planned Gp IIb/IIIa inhibition
Study: 30853361
Drug: Dose-dense taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense taxane chemotherapy (ddTC)
Study: 30853361
Drug: Conventional taxane
Normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional taxane and carboplatin chemotherapy (TC)
Study: 22584132
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir (n = 162)
Study: 22584132
Drug: Continuation without
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation without insulin detemir (n = 157)
Study: 19084016
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a (180 mug) weekly for 48 weeks and ribavirin (1000-1200 mg) daily for HCV genotype 1
Study: 19084016
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a weekly for 24 weeks and ribavirin (800 mg) daily for HCV genotypes 2 or 3
Study: 16915367
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg after pretreatment with clarithromycin 800 mg/day
Study: 16915367
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg after pretreatment with fluvoxamine 50 mg/day
Study: 15736352
Drug: Cyclizine 0.7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclizine 0.7 mg/kg during surgery followed by PCA with cyclizine 2 mg per demand
Study: 15736352
Drug: Droperidol 0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol 0.04 mg/kg during surgery followed by PCA with droperidol 0.05 mg per demand
Study: 10598606
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg rapacuronium
Study: 10598606
Drug: Mivacurium (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (0.25 mg/kg)
Study: 10598606
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (1.5 mg/kg rapacuronium, 2.5 mg/kg rapacuronium, succinylcholine, mivacurium)
Study: 1927129
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with Cisplatin and 5‐Fluorouracil over 6 cycles
Study: 1927129
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with Cisplatin and 5‐Fluorouracil over 3 cycles plus Telecobalt‐irradiation to 50 Gy
Study: 25539762
Drug: Diazepam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam (15 mg daily for 7 days)
Study: 24066672
Drug: 80 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 μg Beraprost Sodium (BPS) daily for 12 weeks
Study: 21852698
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care at time of pregnancy confirmation with sequential partner testing (n = 158)
Study: 21852698
Drug: Secondary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary care by midwives with sequential partner testing (standard care, n = 115)
Study: 9507926
Drug: Incorrect irregular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorrect irregular participle forms (e.g., *prendato instead of preso)
Study: 9507926
Drug: Incorrect regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incorrect regular participle forms (e.g., *parlito, *dormato)
Study: 7530028
Drug: Methoxamine 10
Normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methoxamine 10 mg i.m. 15 min before spinal anaesthesia
Study: 3123118
Drug: gamma-L-glutamyl-L-dopa (gludopa)
Normalized name: gamma-L-Glutamyl-L-cysteinyl-glycine
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma-L-glutamyl-L-dopa (gludopa) at a dose of 25 micrograms min-1 kg-1
Study: 3123118
Drug: gamma-L-glutamyl-L-tyrosine (glutyrosine)
Normalized name: gamma-L-Glutamyl-L-cysteinyl-glycine
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: gamma-L-glutamyl-L-tyrosine (glutyrosine) at a dose of 25 micrograms min-1 kg-1
Study: 30917121
Drug: Combination-prevention-package (behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination-prevention-package (behaviour change communication, condom promotion, HIV testing, voluntary male medical circumcision, referral for anti-retroviral therapy if HIV-positive)
Study: 30917121
Drug: Combination-prevention-package
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination-prevention-package
Study: 29141719
Drug: Chloroquine plus
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloroquine plus primaquine (0.25 mg base/kg/day for 14 days)
Study: 14707788
Drug: GW433908 (908),
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW433908 (908), 1400 mg BID
Study: 14707788
Drug: Nelfinavir (NFV),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nelfinavir (NFV), 1250 mg BID
Study: 7942719
Drug: Endoscopic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic therapy (injection or heater probe therapy)
Study: 2681281
Drug: Sulconazole nitrate
Normalized name: Sulconazole Nitrate
DrugBank: Sulconazole (DB06820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sulconazole nitrate 1% cream applied twice daily
Study: 1090014
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional drugs (Control Group I)
Study: 29309700
Drug: Sublingual buprenorphine
Normalized name: buprenorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual buprenorphine (800 mcg)
Study: 29309700
Drug: Intravenous buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buprenorphine (300 mcg)
Study: 23553992
Drug: 400 or
Normalized name: Nico-400 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 or 2000 IU vitamin D3 daily for 6 months
Study: 21292711
Drug: Training in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training in a modified version of the neonatal resuscitation protocol and single dose amoxicillin coupled with facilitated referral of infants to a health centre
Study: 19691854
Drug: Clonidine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (initial loading dose of 0.15 mg followed by an infusion of 0.5 mg over 24 hours; increased to 0.3 mg, 0.45 mg, and 0.6 mg at subsequent levels)
Study: 16478814
Drug: Testosterone administration
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone administration using a patch that delivers 300 microg daily
Study: 15577594
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ANN and clinical interpretation
Study: 11041065
Drug: Single cytospin
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single cytospin slide preparation
Study: 9001831
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg QID
Study: 6384453
Drug: Trimethoprim-sulfamethoxazole (TMP-SMZ)
Normalized name: sulfamethoxazole / trimethoprim
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim-sulfamethoxazole (TMP-SMZ) administered twice daily
Study: 6384453
Drug: Cefaclor administered
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefaclor administered twice daily
Study: 28368521
Drug: Bolus AVP
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus AVP after CRH infusion
Study: 21422032
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone treatment (PC)
Study: 17533063
Drug: HRT discontinuation
Normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT discontinuation
Study: 15345498
Drug: Etanercept (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (25 mg injections, twice weekly for 12 weeks)
Study: 11141221
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g intravenous ampicillin and sulbactam (AS) before incision
Study: 2914116
Drug: ioxaglate 280
Normalized name: ioxaglate
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioxaglate 280 mg I/ml
Study: 2914116
Drug: metrizoate 280
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: metrizoate 280 mg I/ml
Study: 2914116
Drug: metrizoate 370
Normalized name: Metrifonate
DrugBank: Metrifonate (DB11473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: metrizoate 370 mg I/ml
Study: 4262210
Drug: Carisoprodol 350
Normalized name: carisoprodol 350 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carisoprodol 350 mg, four times daily for four days
Study: 4262210
Drug: Butabarbital 15
Normalized name: butabarbital 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butabarbital 15 mg, four times daily for four days
Study: 4262210
Drug: Placebo, four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, four times daily for four days
Study: 31156218
Drug: Comprehensive rehabilitation
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive rehabilitation including mechanotherapy and cognitive stimulation using tablet technologies
Study: 28005440
Drug: High-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cholecalciferol (300,000 IU)
Study: 28005440
Drug: Low-dose cholecalciferol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cholecalciferol (75,000 IU)
Study: 16963037
Drug: Single-dose GnRH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose GnRH antagonist
Study: 16963037
Drug: Long protocol
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long protocol for GnRH agonist
Study: 9538647
Drug: Hemodialysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemodialysis with the presence of heparin
Study: 29532196
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using GaAlAs diode laser (780 nm, 2 J/spot) applied immediately after surgery and every 24 hours for 3 days.
Study: 29532196
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no laser therapy).
Study: 23558454
Drug: Orofacial regulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orofacial regulation therapy
Study: 23558454
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no mimicry therapy)
Study: 18701642
Drug: Pycnogenol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pycnogenol (150 mg daily for 3 months)
Study: 12818461
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg estradiol
Study: 12818461
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg estradiol
Study: 10083765
Drug: Gemfibrozil 300
Normalized name: gemfibrozil 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemfibrozil 300 mg twice per day
Study: 7729302
Drug: Euglycemic hyperinsulinemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemic hyperinsulinemic clamp (40 mU insulin.m-2.min-1)
Study: 7729302
Drug: Placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo infusion (50 ml isotonic saline)
Study: 2292327
Drug: 0.1% mometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% mometasone furoate cream applied once daily
Study: 2292327
Drug: 0.1% betamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% betamethasone valerate cream applied twice daily
Study: 30517622
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (TVP-)
Study: 21057356
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion strategy (transfusion if hemoglobin <7.0 g/dL)
Study: 21057356
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (transfusion if hemoglobin <9.5 g/dL)
Study: 20581790
Drug: TzCOAD (150-375
Approvals — FDA: no, EMA: no, PMDA: no
Description: TzCOAD (150-375 mg)
Study: 776152
Drug: Piracetam (pyrrolidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (pyrrolidine acetamide) at a dose of 80 mg/kg/day for 10 weeks.
Study: 776152
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group receiving customary treatment only.
Study: 29968937
Drug: Fecal immunochemical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal immunochemical test (FIT) with cut-off levels 20 μg Hb/g and 40 μg Hb/g for one sample
Study: 29968937
Drug: Fecal immunochemical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal immunochemical test (FIT) with mean of two samples at cut-off 40 μg Hb/g and 80 μg Hb/g
Study: 29968937
Drug: Fecal immunochemical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal immunochemical test (FIT) in women with lowered cut-off from 40 to 20 μg Hb/g
Study: 29510001
Drug: Tildrakizumab IV
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab IV doses of 0.1, 0.5, 3 and 10 mg/kg
Study: 29510001
Drug: Tildrakizumab SC
Normalized name: Tildrakizumab
DrugBank: Tildrakizumab (DB14004)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tildrakizumab SC doses of 50 or 200 mg
Study: 17414240
Drug: 20-mg fluoxetine
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-mg fluoxetine
Study: 17414240
Drug: 40-mg fluoxetine
Normalized name: fluoxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40-mg fluoxetine
Study: 15840751
Drug: Monophasic oral
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic oral contraceptive pill with lower dose of norethisterone
Study: 15840751
Drug: Monophasic oral
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic oral contraceptive pill with higher dose of norethisterone
Study: 12402610
Drug: Dressing film
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dressing film method (Group A) - exit site cleaned with povidone iodine solution once weekly, covered with gauze, sealed with dressing film
Study: 12402610
Drug: Dressing film
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dressing film method (Group B) - exit site cleaned with povidone iodine solution once every 2 weeks, covered with gauze, sealed with dressing film
Study: 12402610
Drug: Dressing film
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dressing film method (Group C) - exit site cleaned with povidone iodine solution once every 3 weeks, covered with gauze, sealed with dressing film
Study: 12402610
Drug: Dressing film
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dressing film method (Group D) - exit site cleaned with povidone iodine solution once every 4 weeks, covered with gauze, sealed with dressing film
Study: 12402610
Drug: Dressing film
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dressing film method (Group E) - exit site cleaned with povidone iodine solution once every 5 weeks, covered with gauze, sealed with dressing film
Study: 12402610
Drug: Dressing film
Normalized name: DRESSING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dressing film method (Group F) - exit site cleaned with povidone iodine solution once every 6 weeks, covered with gauze, sealed with dressing film
Study: 12402610
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - exit site cleaned with povidone iodine solution daily, gauze dressing applied
Study: 7881645
Drug: Continuous nebulization
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous nebulization of terbutaline (16 mg over 8 hours)
Study: 7881645
Drug: Intermittent nebulization
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent nebulization of terbutaline (4 mg every 2 hours for 20 minutes)
Study: 417893
Drug: High pressure
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High pressure oxygen (HPO) with six fractions of 600 rad maximum tissue dose
Study: 417893
Drug: Air at
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air at atmospheric pressure with conventional small fraction daily radiotherapy
Study: 28364091
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure treatment (targeting systolic BP <120 mm Hg)